Home Featured Page 212

Featured

Latest

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an Efficacy Signal, and the Role of Expectations

Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté...

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R)...

PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian...

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S....

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as...

Psychedelic Research Bulletin: November 2021

Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix...

EDITOR PICKS

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.